+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication (Oncology, Infectious Diseases), and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • September 2025
  • Region: Global
  • Grand View Research
  • ID: 6176849
REQUEST CUSTOMIZATION
Description Jump to:
The global cell and gene therapy CDMO market size was valued at USD 5.17 Billion in 2025 and is projected to reach USD 27.12 billion by 2033, growing at a CAGR of 23.03% from 2025 to 2033. The industry is driven by the expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, and substantial investments from both public and private sectors in research and development.

The rising demand for outsourced services related to cell and gene therapies, the increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process are also fueling the growth. The market is primarily driven by the increased R&D funding and investments in cell and gene therapeutics (CGT) by the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production are also factors which is driving market growth. According to the data published by clinicaltrials.org there are currently over 2,000 ongoing clinical trials in cell and gene therapies that are progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA’s approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage. Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

Global Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global cell and gene therapy CDMO market report based on phase, product, indication, and region.

Phase Outlook (Revenue, USD Million, 2021-2033)

  • Pre-clinical
  • Clinical

Product Outlook (Revenue, USD Million, 2021-2033)

  • Gene Therapy
  • Gene-Modified Cell Therapy
  • Cell Therapy

Indication Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Cell and Gene Therapy CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Cell and Gene Therapy CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Cell and Gene Therapy CDMO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Cell and Gene Therapy CDMO Market Phase Movement Analysis
4.3. Global Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
4.4. Pre-clinical
4.4.1. Pre-clinical Market Estimates and Forecasts, 2021-2033 (USD million)
4.5. Clinical
4.5.1. Clinical Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Cell and Gene Therapy CDMO Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Cell and Gene Therapy CDMO Market Product Type Movement Analysis
5.3. Global Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
5.4. Gene Therapy
5.4.1. Gene Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.4.2. Ex-vivo
5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021-2033 (USD Million)
5.4.3. In-vivo
5.4.3.1. In-vivo Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Gene-Modified Cell Therapy
5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.2. CAR T-cell therapies
5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.3. CAR-NK cell therapy
5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.4. TCR-T cell therapy
5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.5. Other
5.5.5.1. Other Market Estimates and Forecasts, 2021-2033 (USD Million)
5.6. Cell Therapy
5.6.1. Cell Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Cell and Gene Therapy CDMO Market Indication Movement Analysis
6.3. Global Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Infectious Diseases
6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Neurological disorders
6.6.1. Neurological disorders Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Rare Diseases
6.7.1. Rare Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Europe Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. South Korea Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. MEA
7.8.1. MEA Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Cell and Gene Therapy CDMO Market Share Analysis, 2024
8.3. Company Profiles
8.3.1. Lonza
8.3.1.1. Company overview
8.3.1.2. Financial Performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Catalent, Inc
8.3.2.1. Company overview
8.3.2.2. Financial Performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Cytiva
8.3.3.1. Company overview
8.3.3.2. Financial Performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Samsung Biologics
8.3.4.1. Company overview
8.3.4.2. Financial Performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Thermo Fisher Scientific Inc.
8.3.5.1. Company overview
8.3.5.2. Financial Performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Novartis AG
8.3.6.1. Company overview
8.3.6.2. Financial Performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. WuXi AppTec
8.3.7.1. Company overview
8.3.7.2. Financial Performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. AGC Biologics
8.3.8.1. Company overview
8.3.8.2. Financial Performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. OmniaBio
8.3.9.1. Company overview
8.3.9.2. Financial Performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Charles River Laboratories
8.3.10.1. Company overview
8.3.10.2. Financial Performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Rentschler Biopharma SE
8.3.11.1. Company overview
8.3.11.2. Financial Performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 3 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 4 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 5 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 6 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 7 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 8 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 9 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 10 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 11 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 12 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 13 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 14 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 15 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 16 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 17 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 18 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 19 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 20 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 21 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 22 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 23 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 24 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 25 France Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 26 France Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 27 France Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 28 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 29 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 30 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 31 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 32 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 33 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 34 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 35 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 36 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 37 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 38 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 39 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 40 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 41 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 42 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 43 Asia-Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 44 Asia-Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 45 Asia-Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 46 Asia-Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 47 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 48 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 49 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 50 China Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 51 China Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 52 China Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 53 India Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 54 India Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 55 India Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 56 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 57 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 58 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 59 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 60 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 61 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 62 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 63 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 64 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 65 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 66 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 67 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 68 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 69 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 70 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 71 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 72 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 73 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 74 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 75 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 76 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 77 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 78 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 79 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 80 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 81 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 82 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 83 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 84 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 85 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 86 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 87 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 88 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 89 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 90 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 91 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 92 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 93 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 94 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 95 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021-2033 (USD Million)
Table 96 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
List of Figures
Figure 1 Cell And Gene Therapy CDMO Market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Market formulation & validation
Figure 7 Commodity flow analysis
Figure 8 Value-Chain-Based Sizing & Forecasting
Figure 9 QFD model sizing & forecasting
Figure 10 Bottom-up approach
Figure 11 Market snapshot
Figure 12 Segment snapshot
Figure 13 Segment snapshot
Figure 14 Segment snapshot
Figure 15 Competitive landscape snapshot
Figure 16 Parent market outlook, 2024 (USD Million)
Figure 17 Ancillary market outlook, 2024 (USD Million)
Figure 18 Cell And Gene Therapy CDMO Market dynamics
Figure 19 Total R&D drug pipeline size, 2021-2024
Figure 20 Total drug pipeline by development phase, 2024
Figure 21 Porter’s five forces analysis
Figure 22 PESTEL analysis
Figure 23 Cell And Gene Therapy CDMO Market Phase outlook: Segment dashboard
Figure 24 Cell And Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
Figure 25 Pre-clinical market estimates and forecasts, 2021-2033 (USD Million)
Figure 26 Clinical market estimates and forecasts, 2021-2033 (USD Million)
Figure 27 Cell And Gene Therapy CDMO Market Product Type outlook: Segment dashboard
Figure 28 Cell And Gene Therapy CDMO Market, by Product Type segment: Market share, 2025 & 2033
Figure 29 Gene Therapy Gene-Modified Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 30 Ex-vivo market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 In-vivo market estimates and forecasts, 2021-2033 (USD Million)
Figure 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 33 CAR T-cell therapies market estimates and forecasts, 2021-2033 (USD Million)
Figure 34 CAR-NK cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 35 TCR-T cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 Others market estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 38 Cell And Gene Therapy CDMO Market Indication outlook: Segment dashboard
Figure 39 Cell And Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
Figure 40 Oncology market estimates and forecasts, 2021-2033 (USD Million)
Figure 41 Infectious Diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 Neurological disorders market estimates and forecasts, 2021-2033 (USD Million)
Figure 43 Rare Diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Others market estimates and forecasts, 2021-2033 (USD Million)
Figure 45 Regional market: Key takeaways
Figure 46 Regional marketplace: Key takeaways
Figure 47 North America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 48 Key country dynamics
Figure 49 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 50 Key country dynamics
Figure 51 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 52 Key country dynamics
Figure 53 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 54 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 55 Key country dynamics
Figure 56 UK Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 57 Key country dynamics
Figure 58 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 59 Key country dynamics
Figure 60 France Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 61 Key country dynamics
Figure 62 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 63 Key country dynamics
Figure 64 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 65 Key country dynamics
Figure 66 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 67 Key country dynamics
Figure 68 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 69 Key country dynamics
Figure 70 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 71 Asia-Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 72 Key country dynamics
Figure 73 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 74 Key country dynamics
Figure 75 China Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 76 Key country dynamics
Figure 77 India Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 78 Key country dynamics
Figure 79 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 80 Key country dynamics
Figure 81 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 82 Key country dynamics
Figure 83 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 84 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 85 Key country dynamics
Figure 86 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 87 Key country dynamics
Figure 88 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 89 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 90 Key country dynamics
Figure 91 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 92 Key country dynamics
Figure 93 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 94 Key country dynamics
Figure 95 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 96 Key country dynamics
Figure 97 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 98 Key country dynamics
Figure 99 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 100 Key country dynamics
Figure 101 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 102 Market participant categorization
Figure 103 Heat map analysis

Companies Mentioned

The leading players profiled in this Cell and Gene Therapy CDMO market report include:
  • onza
  • atalent, Inc
  • ytiva
  • amsung Biologics
  • hermo Fisher Scientific Inc.
  • ovartis AG
  • uXi AppTec
  • GC Biologics
  • mniaBio
  • entschler Biopharma SE
  • harles River Laboratories

Table Information

Report AttributeDetails
No. of Pages150
PublishedSeptember 2025
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 5.17 Billion
Forecasted Market Value ( USD ) by 2033 $ 27.12 Billion
Compound Annual Growth Rate23.0%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033 - Product Image

U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033 - Product Image

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

  • Report
  • 336 Pages
  • Global
From
U.S. Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report by Product (Biologics, Biosimilar), Service (Contract Manufacturing, Contract Development), Source, End Use, and Country with Growth Forecasts, 2025-2033 - Product Image

U.S. Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report by Product (Biologics, Biosimilar), Service (Contract Manufacturing, Contract Development), Source, End Use, and Country with Growth Forecasts, 2025-2033

  • Report
  • 120 Pages
  • United States
From
U.S. Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Gene Therapy Media Market Size, Share & Trends Analysis Report by Product (Specialty Media, Serum-free Media), Vector Type (AAV, LV), End Use, and Region with Growth Forecasts, 2026-2033 - Product Image

Gene Therapy Media Market Size, Share & Trends Analysis Report by Product (Specialty Media, Serum-free Media), Vector Type (AAV, LV), End Use, and Region with Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.